For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.
There is nothing more disheartening to me than working with patients who have a treatable disease but are unable to access the most effective treatments for it. As a family ...
Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
The UK healthcare landscape is set for a major shake-up following Prime Minister Keir Starmer’s announcement that NHS England ...
Health associations are urging governments to ensure Canadian patients don't get caught in the crossfire of the ongoing trade ...
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback